News >

Atezolizumab Prolongs Survival in SCLC

Kristie L. Kahl
Published: Tuesday, Sep 25, 2018

Stephen V. Liu, MD

Stephen V. Liu, MD

The addition of atezolizumab (Tecentriq) to standard carboplatin and etoposide in the frontline setting significantly prolonged survival in patients with extensive-stage small cell lung cancer (ES-SCLC) compared with the chemotherapy regimen alone.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication